144 related articles for article (PubMed ID: 26282646)
1. Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?
Yurgelun MB; Hiller E; Garber JE
J Clin Oncol; 2015 Oct; 33(28):3092-5. PubMed ID: 26282646
[No Abstract] [Full Text] [Related]
2. Two double heterozygotes in a South African Afrikaner family: implications for BRCA1 and BRCA2 predictive testing.
Loubser F; de Villiers JN; van der Merwe NC
Clin Genet; 2012 Dec; 82(6):599-600. PubMed ID: 22486351
[No Abstract] [Full Text] [Related]
3. Population Frequency of Germline BRCA1/2 Mutations.
Maxwell KN; Domchek SM; Nathanson KL; Robson ME
J Clin Oncol; 2016 Dec; 34(34):4183-4185. PubMed ID: 27551127
[No Abstract] [Full Text] [Related]
4. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
[TBL] [Abstract][Full Text] [Related]
5. Two patients with germline mutations in both BRCA1 and BRCA2 discovered unintentionally: a case series and discussion of BRCA testing modalities.
Augustyn AM; Agostino NM; Namey TL; Nair S; Martino MA
Breast Cancer Res Treat; 2011 Sep; 129(2):629-34. PubMed ID: 21607582
[TBL] [Abstract][Full Text] [Related]
6. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
7. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
8. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
Ticha I; Kleibl Z; Stribrna J; Kotlas J; Zimovjanova M; Mateju M; Zikan M; Pohlreich P
Breast Cancer Res Treat; 2010 Nov; 124(2):337-47. PubMed ID: 20135348
[TBL] [Abstract][Full Text] [Related]
9. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors.
Arnold JM; Choong DY; Thompson ER; ; Waddell N; Lindeman GJ; Visvader JE; Campbell IG; Chenevix-Trench G
Breast Cancer Res Treat; 2010 Jan; 119(2):491-6. PubMed ID: 19189213
[TBL] [Abstract][Full Text] [Related]
10. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
[TBL] [Abstract][Full Text] [Related]
11. [Genetic testing in patients at risk for carcinoma of the breast].
Kiechle M
Dtsch Med Wochenschr; 2006 Oct; 131(43):2420-2. PubMed ID: 17054060
[No Abstract] [Full Text] [Related]
12. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
[TBL] [Abstract][Full Text] [Related]
13. Large genomic rearrangements in BRCA1 and BRCA2: implications for patient care.
Mahon SM
Oncol Nurs Forum; 2013 May; 40(3):220-2. PubMed ID: 23615136
[No Abstract] [Full Text] [Related]
14. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A
Crit Rev Oncol Hematol; 2006 Jan; 57(1):1-23. PubMed ID: 16337408
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and BRCA2 germline mutations in Korean breast cancer patients at high risk of carrying mutations.
Ahn SH; Son BH; Yoon KS; Noh DY; Han W; Kim SW; Lee ES; Park HL; Hong YJ; Choi JJ; Moon SY; Kim MJ; Kim KH; Kwak BS; Cho DY
Cancer Lett; 2007 Jan; 245(1-2):90-5. PubMed ID: 16455195
[TBL] [Abstract][Full Text] [Related]
16. [Current aspects of breast carcinoma: 2].
Petru E
Wien Med Wochenschr; 2010 Nov; 160(19-20):477. PubMed ID: 20972710
[No Abstract] [Full Text] [Related]
17. Clinical implications of hereditary breast cancer.
Quan ML; Petrek JA
Adv Surg; 2003; 37():197-212. PubMed ID: 12953634
[No Abstract] [Full Text] [Related]
18. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
de la Cruz J; Andre F; Harrell RK; Bassett RL; Arun B; Mathieu MC; Delaloge S; Gilcrease MZ
Hum Pathol; 2012 Nov; 43(11):1932-9. PubMed ID: 22591913
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
20. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history.
Lalloo F; Varley J; Ellis D; Moran A; O'Dair L; Pharoah P; Evans DG;
Lancet; 2003 Mar; 361(9363):1101-2. PubMed ID: 12672316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
